- Home
- LPTH vs TVRD Comparison
LPTH vs TVRD Comparison
Compare LPTH & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTH
- TVRD
- Stock Information
- Founded
- LPTH 1985
- TVRD 2017
- Country
- LPTH United States
- TVRD United States
- Employees
- LPTH N/A
- TVRD N/A
- Industry
- LPTH Semiconductors
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- LPTH Technology
- TVRD Health Care
- Exchange
- LPTH Nasdaq
- TVRD Nasdaq
- Market Cap
- LPTH 229.5M
- TVRD 246.5M
- IPO Year
- LPTH 1996
- TVRD N/A
- Fundamental
- Price
- LPTH $6.40
- TVRD $34.72
- Analyst Decision
- LPTH Strong Buy
- TVRD Strong Buy
- Analyst Count
- LPTH 3
- TVRD 5
- Target Price
- LPTH $5.33
- TVRD $59.20
- AVG Volume (30 Days)
- LPTH 1.6M
- TVRD 22.8K
- Earning Date
- LPTH 11-06-2025
- TVRD 08-14-2025
- Dividend Yield
- LPTH N/A
- TVRD N/A
- EPS Growth
- LPTH N/A
- TVRD N/A
- EPS
- LPTH N/A
- TVRD N/A
- Revenue
- LPTH $33,626,969.00
- TVRD N/A
- Revenue This Year
- LPTH $19.59
- TVRD N/A
- Revenue Next Year
- LPTH $47.43
- TVRD N/A
- P/E Ratio
- LPTH N/A
- TVRD N/A
- Revenue Growth
- LPTH 2.59
- TVRD N/A
- 52 Week Low
- LPTH $1.11
- TVRD $8.13
- 52 Week High
- LPTH $6.97
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- LPTH 58.73
- TVRD 68.09
- Support Level
- LPTH $5.17
- TVRD $33.51
- Resistance Level
- LPTH $5.59
- TVRD $36.71
- Average True Range (ATR)
- LPTH 0.41
- TVRD 2.03
- MACD
- LPTH -0.27
- TVRD 0.33
- Stochastic Oscillator
- LPTH 93.90
- TVRD 76.85
About LPTH LightPath Technologies Inc.
LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.